Ryotaro Yamada on Muck Rack

Ryotaro Yamada

Verified
Palo Alto
As seen in: Nikkei, Nikkei Asia, PLOS, DealStreetAsia, Caixin Global, Annals of Vascular Surgery
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Ryotaro

Contact Ryotaro, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Fintech startup Alpaca becomes first Japan-founded unicorn in US

|
By Ryotaro Yamada Verified
| DealStreetAsia Verified
Alpaca Chief Product Officer Hitoshi Harada, left, and CEO Yoshi Yokokawa. Photo: Alpaca
Open in Who Shared Issue with article?

China-Linked Self-Driving Startup TuSimple to Delist in U.S.

|
By Ryotaro Yamada Verified
| Caixin Global
00:00/00:00 您的浏览器不支持 audio 标签。 Listen to this article 1x (Nikkei Asia) — TuSimple Inc., a U.S.-based developer of self-driving truck technology with Chinese ties, has applied to delist from Nasdaq, with its market value dwindling to around 1% of its peak amid commercialization delays and rising interest rates. TuSimple expects its stock to go off the market around Feb. 8, and will deregister with the Securities and Exchange Commission as well, according to Wednesday’s announcement.
Open in Who Shared View Duplicates (4) Issue with article?

Effects of the Current Japanese Guideline for Dedicated, Intensive Lipid-lowering Therapy on Lipid Profile and Coronary Events in Patients After Acute Coronary Syndrome

|
By Doreen Tan, Gheorghe-Andrei Dan, Ryotaro Yamada Verified, Teruyoshi Kume
| japscjournal.com
Abstract Background: Patients with acute coronary syndrome (ACS) still have high rates of recurrent adverse cardiovascular events. The purpose of this study was to evaluate the effects of changes in the Japan Atherosclerosis Society Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases for intensive lipid-lowering therapy on the prescription status, lipid profile and clinical outcomes among Japanese patients with ACS.
Open in Who Shared Issue with article?
See all 12 licensed articles (80 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified